Table 3.
Stratification analyses for the association between TP53 rs1042522 C>G polymorphism and hepatoblastoma susceptibility
| Variables | CC | CG/GG | Crude OR | P | Adjusted OR a | P a |
|---|---|---|---|---|---|---|
| (Cases/Controls) | (95% CI) | (95% CI) | ||||
| Age, months | ||||||
| <17 | 36/129 | 78/325 | 0.86 (0.55-1.34) | 0.506 | 0.86 (0.55-1.34) | 0.499 |
| ≥17 | 34/155 | 65/349 | 0.85 (0.54-1.34) | 0.482 | 0.85 (0.54-1.34) | 0.483 |
| Gender | ||||||
| Females | 27/118 | 57/261 | 0.95 (0.58-1.59) | 0.857 | 0.95 (0.57-1.57) | 0.833 |
| Males | 43/166 | 86/413 | 0.80 (0.54-1.21) | 0.294 | 0.81 (0.54-1.21) | 0.298 |
| Clinical stages | ||||||
| I+II | 28/284 | 69/674 | 1.04 (0.66-1.65) | 0.874 | 1.04 (0.66-1.65) | 0.858 |
| III+IV | 23/284 | 32/674 | 0.59 (0.34-1.02) | 0.059 | 0.59 (0.34-1.03) | 0.062 |
a Adjusted for age and gender, omitting the corresponding stratification factor.